
What We're Reading: Christie Vetoes Diabetes Prevention Program
A pocket veto ends hopes of Medicaid coverage for the Diabetes Prevention Program, MannKind partners with a pain medication manufacturer, and Governor Terry Branstad finds more Medicaid managed care woes.
Add the Diabetes Prevention Program (DPP) to the list of causes that have become casualties of New Jersey Governor Chris Christie’s campaign for president. The governor failed to act on a bill to require Medicaid coverage for the evidence-based DPP, even though both houses of the Legislature passed it by overwhelming margins as the 2014-2015 session concluded. In a letter to the diabetes advocacy community, Samuel Grossman, PharmD, CDE, RPh, American Diabetes Association (ADA) advocacy chair for New Jersey, explains that Christie’s use of the “pocket veto” will not deter the ADA from continuing its fight for the bill, which also ensured access to self-management education and nutritional therapy. Still, he writes, "This is a very disappointing and huge setback for Medicaid coverage in New Jersey."
Gov. Chris Christie
Christie has spent little time in the state while campaigning for the 2016 Republican presidential nomination, and several popular bills suffered the pocket veto. Christie’s spokesman complained that the Legislature passed
Report finds managed care miscalculations. The hits just keep coming for Iowa Governor Terry Branstad and his effort to implement Medicaid managed care. An investigation in the
MannKind in the pain business? The creator of the inhaled insulin Afrezza got some good news early today when it announced a collaboration with the Seattle-based Receptor Life Sciences to develop inhaled therapies to treat chronic pan, neurological diseases, and inflammatory disorders.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.